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1. Introduction
Diabetes as a major public health problem
Diabetes is a chronic disease marked by uncontrolled blood glucose,
which is the fifth leading cause of death by disease in the U.S [1]. Prevalence of
diabetes in the general US population is steadily increasing with recent data
indicating that 7.7% of adults have diagnosed diabetes and 5.1% is undiagnosed
with diabetes [2]. Another 29.5% of the population is at risk of diabetes based on
having pre-diabetes. Overall, approximately 40% of the U.S. population has
some hyperglycemic condition [2]. Diabetes and its complications remain major
causes of morbidity and mortality in the U.S.
The effects of diabetes can have a life-long impact on patients. Diabetes is
associated with higher rates of lost work time, disability, and premature mortality.
People with diabetes are at higher risk for heart disease, blindness, kidney failure,
extremity amputations, and other chronic conditions [1]. People with diabetes
have higher use of hospital inpatient care, outpatient and physician office visits,
emergency visits, nursing facility stays, home health visits, visits with other health
professionals, and prescription drug and medical supply use than their peers
without diabetes [3].
The economic impact of diabetes is extensive. A significant portion of
health care expenditures is attributed to diabetes and its complications [3]. The
national cost of diabetes has grown to $156 billion and will increase to $192
billion by 2020 [1]. The actual future costs are likely to be higher than these
projected amounts if the prevalence of diabetes continues to grow, which is
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correlated to the growing problem of obesity. Because of these complications,
diabetes exacts great personal and societal costs.
With the prevalence of diabetes growing, one reason behind it is the
lifestyle that Americans live. With many not understanding or knowing what is
involved in leading a healthy, nutritious lifestyle; that ultimately impacts causing
unhealthy eating and living habits. Diabetes can lead to serious complications
and premature death, but people with diabetes can take steps to control the
disease and lower the risk of complications.
Type 2 diabetes mellitus is a progressive and complex disorder that is
difficult to manage effectively. Majority of patients are overweight or obese at
diagnosis and will be unable to achieve or sustain near normal glycemia without
oral anti diabetic agents [6]; a sizeable proportion of patients will eventually
require insulin therapy to maintain long-term glycemic control, either as monotherapy or in conjunction with oral anti-diabetic therapy. The frequent need for
escalating therapy is held to reflect progressive loss of islet β-cell function,
usually in the presence of obesity-related insulin resistance. [4]
Alpha-glucosidase inhibition for diabetes management
Today's clinicians are presented with an extensive range of oral antidiabetic drugs for management of type 2 diabetes. The main classes are
heterogeneous in their modes of action, safety profiles, and tolerability.
According to the Anti-diabetic Agents Study, “These main classes include agents
that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues),
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reduce hepatic glucose production (biguanides), delay digestion and intestinal
absorption of carbohydrate, α-glucosidase inhibitors, (AGI’s) or improve insulin
action (thiazolidinediones)” [4].
Digestion of dietary carbohydrates primarily occurs in the small intestine
by α-amylase to yield both linear maltose and branched isomaltose
oligosaccharides, neither of which can be absorbed into the bloodstream without
further hydrolysis by α-glucosidases to release glucose. Therefore, intestinal αglucosidases play a crucial role in controlling postprandial blood glucose. For this
reason, one attractive prevention and/or treatment strategy for type-2 diabetes is
the inhibition of α-glucosidase.
The effectiveness of AGI’s for diabetes treatment is well documented in
numerous animal and human clinical studies. For instance, Acarbose has been
shown to reduce postprandial serum glucose and insulin concentrations [5],
improve metabolic control and produce a dose-dependent amelioration of
diabetic nephropathy in the diabetic (db/db) mouse [6]. Acarbose also exerts
beneficial effects on ischemia/reperfusion damage [7] and pancreatic islet
damage by attenuating hyperglycemia [8]. In addition, it has been shown that αglucosidase inhibitor prevents age-related glucose intolerance [5] and improves
insulin sensitivity in fructose-fed rats [9], thus, providing additional evidence for
an anti-diabetic effect of α-glucosidase inhibitors.
Therefore, AGI’s have been used as anti-diabetic drugs to delay the
breakdown of carbohydrate in the gut, and consequently slow the absorption of
sugars, which will consequently lower postprandial insulin levels [10].
Alpha-glucosidase inhibitors and their side effects
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Typical examples of current AGI’s are Acarbose, Miglitol, and Voglibose.
They decrease both postprandial hyperglycemia and hyperinsulinemia, and
thereby may improve sensitivity to insulin and release the stress on β-cells [11].
These compounds do not induce hypoglycemia and have a good safety profile,
although gastrointestinal adverse effects may limit long-term compliance to
therapy [10]. Acarbose is currently the only oral anti-diabetes agent approved for
the treatment of both pre-diabetes and type 2 diabetes [12]. However, it has been
associated with significant side effects. For instance, Acarbose is a
pseudotetrasaccharide that inhibits intestinal α-glucosidase reversibly at the
brush border of intestinal mucosa [13] as well as the pancreatic alpha amylase.
Acarbose being a non-specific inhibitor, inhibits both α-glucosidase and αamylase. The inhibition of α-amylase produces serious gastrointestinal (GI) side
effects, which can increase complications. Pancreatic alpha-amylases hydrolyze
complex starches to oligosaccharides in the lumen of the small intestine. These
are then acted on by α-glucosidases and further degraded to glucose, which is
absorbed into the blood-stream [14]. Inhibition of alpha-amylase results in large
amount of undigested carbohydrates entering into the colon [15]. In the colon,
bacteria digest the complex carbohydrates causing gastrointestinal side effects
such as diarrhea, flatulence, abdominal discomfort, and bloating [16]. These
symptoms are commonly observed and significantly restrict the use of AGIs. GI
events caused a high rate of patient withdrawal in clinical trials involving these
compounds [17]. In particular, the use of Acarbose has been associated with
adverse GI side effects [10, 18] such as bloating, abdominal discomfort, diarrhea,
and flatulence, which occur in about 20% of patients taking this drug [19]. With
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respect to preventing type 2 diabetes, these potential side effects are of
particular importance in medication used by persons with impaired glucose.
Therefore, specific inhibitors of alpha-glucosidases are preferable in order to
reduce GI side effects associated with current AGI’s that also inhibit alphaamylase.
Grape Pomace
In the past three decades, considerable research effort has been devoted
to the discovery and development of novel active AGI’s since they are potential
therapeutic agents for diabetes. A variety of natural compounds and extracts
have already been identified as being beneficial in the treatment of diabetes [2025].

In particular, phenolic compounds found in plants (i.e. tea, raspberries,

strawberries, blueberries, and blackcurrants) have been found to be involved in
the inhibition of α-glucosidase [26, 27]. For instance, green tea extract has been
shown to inhibit rat intestinal α-glucosidases with an IC50 of 0.735mg/ml [25].
The oral administration of green tea extract (300mg/kg bw for 4 weeks)
remarkably reduced the fasting blood glucose (by 54%) in STZ-induced diabetic
rats [28].

A procyanidins-rich pine bark extract (Pycnogenol®) was recently

shown to potentially inhibit α-glucosidases, which has been associated with its
anti-diabetic effect in patients with type 2 diabetes [20, 29]. A group of natural
acylated anthocyanins also show α-glucosidase inhibitory activity [26].
Grape pomace extract (GPE) was recently reported to selectively inhibit
alpha-glucosidases without inhibiting alpha-amylase, leading to inhibition of
postprandial hyperglycemia in diabetic animals [30], suggesting that grape
pomace components may have a novel anti-diabetic effect.

--
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Grape, Vitis vinifera, is one of the most popular and widely cultivated fruits
in the world. Grape contains several active components including flavonoids,
polyphenols, anthocyanins, proanthocyanidins, procyanidins, and the stilbene
derivatives resveratrol [31]. There is growing interests on phenolic compounds
found within grapes focusing on their biological activities linking to human health
benefits such as antioxidant, cardio-protective, anticancer, anti-inflammation,
anti-aging and antimicrobial properties [31].
These bioactive components of grape mainly exist in grape skin and
seeds. Grape pomace, which is made up of the skins, seeds and stems are
discarded during winemaking [32]. These wastes contain bioactive components
with potent antioxidant and free radical scavenging activity. These chemical
compounds have been linked to various health benefits. GPE and components
have been widely studied for their antioxidant and other health-promoting
properties [17]. However, very few studies have investigated the potential of
grape pomace as an alternative bio-resource for diabetes management [30].
Currently the only research, conducted by our laboratory has reported that GPE
has an inhibitory activity, exerting a significant anti-postprandial hyperglycemic
effect, suggesting that grape pomace could be a valuable food derived bioresource that is rich in antioxidants and anti-hyperglycemic compounds [30].

--
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2. Objectives of this Study
Our long-term goal is to develop a potential dietary intervention for diabetes
management from GPE. The specific objective of this research is to prepare
more effective GPE by fractionating and isolating active compounds that inhibit
alpha-glucosidases in a specific GPE. The data obtained from this study will help
identify the perimeters/ conditions that optimize the preparation of GPE and its
components will lead to future animal and/or human studies to further determine
their potential in preventing and treating Type-2 diabetes.

--
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3. Materials and Methods
Materials and reagents
Yeast type I α-glucosidase (EC 3.2.1.20, G5003), rat intestinal acetone
powder (N1377-5G), p-nitrophenyl α-D-glucoside (pNPG), silica gel and C-18
were all purchased from the Sigma Chemical Co. (St. Louis, MO, USA).
Acarbose (A0802) was purchased from LKT Laboratories Inc,(St. Paul, MN).The
HTS 7000 Bio Assay Reader was acquired from MTX Lab Systems Inc Plate,
Perkin Elmer (Norwalk, Ct). The BUCHI Roto-evaporator R-124 and water bath
B-481was acquired from GoIndustry DoveBid, (Westbury, NY).The HPLC Hitachi
Elite LaChrom Autosampler L-2200 was purchased from HITACHI, Japan. The
glassware 45/50 Synthware, Chemglass 24/40 1000 ml were purchased from
Fisher Scientific Co (Hampton, New Hampshire). The butanol, ethanol and
methanol solvent was HPLC grade (Fisher Scientific Co.)

Experimental protocols
1. GPE preparation
Air dried red grape pomace supplied Dr. John Parry at Virginia State
University was grounded to fine powder. The powder (50g) was extracted with
500 ml of 70% ethanol under stirring overnight. The supernatant was filtered on
a Büchner funnel and collected.

The supernatant was concentrated by the

BUCHI Roto-evaporator (Westbury, NY).

The rotary evaporator was used to

remove the organic solvents from the extract without excessive heating of the
sample (set at 60°C). The concentrated GPE was collected and placed into a
weighed vial. A small amount of methanol or ethanol was added to rinse and
collect the residue. The concentrated GPE was placed under the hood to
completely dry.
2. GPE fractionation and purification

--
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2.1 Liquid-liquid separation
The separatory funnel was used in liquid-liquid extractions to separate
(partition) the components of a mixture between two immiscible solvent phases
of different densities. The concentrated GPE was poured into a separator funnel
then Butanol and water were added to the funnel. The funnel was vigorously
inverted several times to mechanically mix up the two solvents. The funnel was
settled for the phases to separate. If it was difficult to distinguish between the
layers more butanol was added as needed. Butanol and water are incompatible
so the water will settle at bottom. Once the layers are distinguished, water was
released out of the funnel. The partition was repeated six more times to ensure a
more thorough separation of compounds into butanol fraction.
2.2 Open column chromatography
Column chromatography was used to separate compounds from the
active fraction (identified by alpha-glucosidase assay) in. An open glass column
(Chemglass 24x40) was used. Cotton was placed at the bottom of the column to
prevent the stationary phase from being washed out. The column was originally
packed using silica gel. Separation was unsatisfactory using this method. The
column was then packed with 100mg of C18 (10 micron) via the dry method and
activated with ethanol. The GPE fraction was reconstituted with 15% methanol
and loaded into the column. It was eluted with aqueous methanol system. A
range of ratios were used for the column: 30% MEOH 70% H20, 50% MEOH
50 % H20, and 70% MEOH 30 % H20.
Twenty fractions were collected based on different affinity between
stationary and mobile phases, all listed in Figure 1. All the collected fractions
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were subjected to thin layer chromatography test and those with the same
components were combined for alpha-glucosidase assay.
2.3 Thin layer chromatography (TLC)
TLC was performed to determine whether the fractions collected were
different or the same. After comparison, fractions with a similar pattern were
combined. Thin layer chromatography was performed on a sheet of aluminum
foil coated with a thin layer of absorbent material usually silica gel. This layer of
adsorbent is known as the stationary phase. A portion of the fractions were
dissolved in methanol and a small drop was placed on the base line of the plate
about 1.5 cm from the bottom of the edge. Allow the sample to completely dry
using a blow-dryer.

A small amount of appropriate solvent; ethyl acetate,

methanol, water in the ratio of 60/40/2 with 2 drops of acetic acid, was poured
into a glass beaker. The TLC plate was placed into the beaker, making sure the
spots of the sample don’t touch the solvent and the lid is closed. The solvent was
drawn up the plate by capillary action. The mobile phase flowed through the
stationary phase and carried The solvent was drawn up the plate by capillary
action. The mobile phase flowed through the stationary phase and carries the
components of the mixture with it. the components of the mixture with it. When
the solvent reaches no higher than top of the TLC plate, the plate was removed
using tweezers. The TLC plate was placed on the side to dry. Different
components traveled at different rates and the dried plate was scanned under UV
light to detect spots that contain separated components.
2.4 Rotary evaporation of GPE fractions

--
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The fractions collected from open column chromatography with the same
TLC pattern were combined and further concentrated using a BUCHI Rotary
Evaporator R-124, (Westbury, NY). The concentrated fractions were then airdried in a fume hood and immediately stored in a -20°C freezer.
3. Prepare reagents for enzyme assay
Preparing stock and working solutions for enzymatic experiments: After all
GPE fractions have been collected and completely dried, 2 mg of each fraction
was placed into a small centrifuge tube and methanol was added to get a
concentration of 2 mg/ml. Serial dilutions were made to prepare working GPE
solutions to test activity.
3.1 Prepare Acarbose stock and working solution
Ten mg of Acarbose was dissolved in 10 mL 0.1 M phosphate buffer (PB,
pH 6.8) to achieve a 1 mg/mL stock solution. Fifty µL of above solution was
mixed with 4.95 mL 0.1 M PB pH 6.8 to achieve a 10 µg/mL working solution.
Use a vortex mixer to obtain a homogeneous mix
3.2 Prepare substrate PNPG solutions in PB buffer
P-nitrophenyl-α-d-glucopyranoside (pNPG) is a universe substrate of αglucosidases, which was used as the substrate for intestinal α-glucosidases in
our experiments Sixty milligram of pNPG powder was dissolved in 50 mL 0.1 M
PB pH 6.8 to achieve a 4 mM concentration.
3.3 Prepare rat intestinal α-glucosidases
Rat intestinal powder (2.5g) was suspended in 100 mL of 0.1 M PB (pH
6.8). The suspension was shaken overnight and the supernatant was collected
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upon centrifugation and filtration using 0.45 µm of coarse filter paper. For
experiments, the dried enzyme extract was weighed and dissolved in 0.1 M PB
pH 6.8 to achieve a 25mg/ mL concentration.
4. Enzyme Assay
One hundred µl of each sample was loaded into each well of the 96 well plate.
One hundred µl of Acarbose (10 µg/mL) and solvent used to dissolve GPE (5%
Methanol and 95% H20) were used as positive and negative controls. The
reaction was initiated by the addition of 100 µl of α-glucosidase enzyme and 50
µl of substrate (pNPG) into all wells. Absorbance readings of assay were
recorded at 450nm with shaking using HTS 7000- Bio Assay Reader- Perkin
Elmer (Norwalk, Ct). The α-glucosidase inhibitory activity was expressed as %
inhibition.
5. High performance liquid chromatography (HPLC)
The HPLC (Hitachi, Schaumburg, IL) was used for the separation of the
active fractions identified in the alpha-glucosidase assay for qualitative and
quantitative analysis of potential active compounds. An analytical C18 (250x5mm)
was used for separation and a diode array detector (DAD) was used to monitor
fractions and compounds eluted from the column. Twenty mg of active fraction
was dissolved in 2 ml methanol. The solution was filtered via 0.45 µm of filter
paper and placed in a vial. A variety of mobile phases and programs (described
below) were developed to optimize the separation. A gradient program was
chosen since the isocratic separation was not satisfactory for separation.
Methanol and water was used first for the mobile phase gradient. After series of
tests, it was concluded that acetonitrile and water gradient method provided the

--
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4. Results and Discussion
Alpha-glucosidase inhibition by GPE and its fractions
GPE has been identified as an inhibitor of α- glucosidase in our previous
studies. Our goal was to identify active fractions or components in GPE. The
initial liquid-liquid partition of GPE led two fractions: water and butanol fractions.
In our preliminary separation, we tried liquid-liquid separation into three phases:
water, butanol, and ethyl acetate and found that the ethyl acetate fraction was
the most effective fraction followed by the butanol fraction via the α -glucosidase
assay. However, the ethyl acetate fraction contained very little amounts of
compounds. In the following separation, we were only using water and butanol
for partitioning. The butanol fraction was further subject to open column
chromatography.
Open column chromatography
From the fractions assayed slight inhibition was recorded in sub fraction 1.
The α-glucosidase inhibitory activity was expressed as % inhibition listed in
Figure 2. In comparison to the other fractions from the column, fraction 1 had the
highest inhibitory effects at 35% compared to the positive control 87.64% and
negative control -.565% listed in Figure 3.
HPLC analysis on the fraction 1
Fraction 1 was further separated via HPLC to determine which
compounds were within that fraction and more specifically, which compound
possibly inhibited the enzyme alpha glucosidase. The sample was prepared and
tested using a wide range of method systems and wavelengths. Methanol mixed
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with water was first chosen as the mobile phase but displayed insufficient
separation on C18 column since the peaks were crowded together. After a series
of method development, we determined that the gradient system of acetonitrile
(ACN) and water, wavelength 210 nm, and injection volume of 20 µl displayed
optimal absorption and was used for collection of compounds. ACN was selected
because it had low noise in UV detection and resulted in less ghost peaking for
gradient baselines. The polarity is lower and it can interact with the molecules to
provide better peak separation. The HPLC chromatograms and methods are
shown in Figures 4-8.
Open column chromatography of GPE for scaling up
As above showed, we have successfully isolated and collected two
compounds (peaks) from the active fraction 1. However, the amounts of the
compounds were too little (less than 0.2 mg) to conduct structure elucidation. In
order to obtain a sufficient amount of the compounds for activity and structure
analysis, we tried to develop an alternative fractionation and separation
procedure that could allow for scaling up. In this method development, GPE was
recreated with the protocol slightly changed. The column was packed with Diaion
Resin instead of C18. Diaion Resin (HP-20) was used because it has much
larger sample capacity than C18 does. We collected the new fraction in hope of
having a larger active sample amount for further testing. When the activity was
tested on GPE using the assay there was no inhibition noticed in any of the
fractions separated from the second column. Possible reasons why the second
column produced no activity could be because the active compounds may work
synergistically and they lose their activity once being fractionated by HP-20. The
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method employing C18 is probably the best for purity of the fraction, but it would
not be the best method quantitatively. We further tried with an open column
loaded with coarse C18 resin to separate GPE and collected over 30 fractions.
However, none of these fractions exerts significant inhibition on alphaglucosidase.
Other reasons why inhibition could have been affected
The butanol fraction of GPE displayed inhibition on rat intestinal alphaglucosidases. With the Grape pomace being mixed with other compounds this
could have had a negative effect limiting its activity. The bioactivity of GPE could
possibly be reduced once it is separated if the compounds have a synergistic
effect. There is also a possibility of the fractions having an inhibitory effect for a
limited amount of time. Subjecting the dried Grape Pomace to high temperatures,
color extractions and distillation could have had a significant effect on the
inhibitory activity of the alpha glucosidase enzyme. There is the possibility that
concentrations could also be too low at this level and inhibition could not be
observed. From this ongoing research there is activity noted in GPE but there
could be many reasons to why it is difficult to notice higher levels of inhibition in
the subsequent fractions of GPE. Fraction 1 showed significant inhibition of alpha
glucosidase, but analyzing the results with the control, the absorbance levels
were still low and not consistent enough to make a clear inference.

--
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5. Conclusion
We identified an active fraction (F1) from GPE, through open column and
HPLC, which had inhibitory effects to alpha glucosidase. The further HPLC
separation yielded two major peaks. The two major peaks were collected and will
undergo

future

structure

identification

and

elucidation.

After

structure

identification and elucidation is complete; testing will be conducted to the
compounds, using the bio-assay reader, identifying their activity. If the
compounds are active we will continue with the method listed above. We have
tried open column chromatography using HP20 and coarse C18 for scale-up of
GPE separation but the resulting fraction failed to show significant inhibition on
alpha-glucosidases. Further method development is needed if the collected
peaks are not active compounds.

--
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Appendix A: Figures
Figure 1
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Figure 1- The process Grape pomace extract separation
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Figure 2
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Figure 2 - Percent Inhibition of Grape Pomace Fractions
Percent inhibition of alpha- glucosidase from grape pomace fractions. Enzyme
assay conducted with absorbance wavelength 450nm. F1 has the highest
percent inhibition of 35% compared to other fractions. Bars with different
superscript values are significantly different from each other (p <0.05).
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Figure 3
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Figure 3- Comparison of Percent Inhibition to control
Enzyme assay conducted with wavelength 450nm. Percent inhibition of F1
compared to Acarbose (positive control) and 5% methanol and 95 % water
(negative control). F1 showed positive inhibitory effects when compared to the
positive and negative controls. Bars with different superscripts/subscripts values
are significantly different from each other (p <0.05).
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Figure 5
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Figure 5- Method 2
A different method was employed using gradient system of methanol and water
for HPLC testing. The chromatogram results still did not show possible
compounds. The timing of the mobile phase needed to be down, to view the
other compounds that could possibly be in the sample. Gradient systems were
used as follows: 0-5 min 80% methanol, 20-23 min 100% methanol, 25-30 min
80 % methanol.
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Figure 6
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Figure 6- Method 3
This chromatogram was altered by increasing water in column to extend out the
timing the peaks occurred. The time was also increased to observe the other
possible compounds. Gradient systems were used as follows: 0-3min 10%
methanol, 18-21min 30%methanol, 31-36 min 60% methanol, 46-50 min 95%
methanol, 56-60 min 90% methanol.
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Figure 7
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Figure 7- Method 4
ACN was introduced into the gradient system. The injection volume was
increased to 30ul. Gradient systems were used as follows: 0-3min 10%
acetonitrile, 18-21 min 30% acetonitrile, 31-36min 60% acetonitrile, 46-50 min
95% acetonitrile 56-60min 90% acetonitrile.
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Figure 8
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Figure 8- Method 5
We determined that for separtion ACN was a preferable solvent to separate the
fraction 1. The injection volume was reduced to 20µl because the original
injection made the peak too high. This chromatogram provided better peaks and
2 compounds were observed. We continued to adjust the method slightly to
separate the peaks from each other and begin to collect the compound. Gradient
systems were used as follows: 0-3 min 10% acetonitrile, 15-30 min 20%
acetonitrile, 40-46 min 50% acetonitrile, 50 min 90 % acetonitrile, 54 min 95%
acetonitrile, 57-60 min 90% acetonitrile.
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Diabetes and its complications are steadily growing and remain major
causes of morbidity and mortality in the U.S. Intestinal α-glucosidases play a
crucial role in controlling postprandial blood glucose. For this reason, one
attractive prevention and/or treatment strategy for type-2 diabetes is the inhibition
of α-glucosidase. The effectiveness of α-glucosidase inhibitors (AGI’s) for
diabetes treatment is well documented in numerous animal and human clinical
studies. Grape pomace extract (GPE) has recently found in our laboratory to
selectively inhibit alpha-glucosidases without inhibiting alpha-amylase, leading to
inhibition of postprandial hyperglycemia in diabetic animals. The present study
was designed to identify effective GPE by fractionating and isolating active
compounds that inhibit alpha-glucosidases in a specific GPE. From enzyme
assay testing, results revealed Fraction 1 active, showed 35% inhibition (p <0.05)
compared to the positive control 87.64% and negative control -.565%. HPLC was
conducted on F1, which yielded two potential active compounds (peaks)
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following ACN gradient system method. F1 will undergo future structure
identification and elucidation.
Fractionation of GPE yielded a very small amount of active F1 for testing. Open
column chromatography using HP20 and coarse C18 for scale-up of GPE
separation but the resulting fraction failed to show significant inhibition on alphaglucosidases. Further method development is needed if the collected peaks are
not active compounds.
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